Transplantation of Mesenchymal Stem Cells Exerts a Greater Long-Term Effect than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Model in Rat

Abstract

The aim of this study is to assess the long-term effect of mesenchymal stem cells (MSC) transplantation in a rat model of chronic myocardial infarction (MI) in comparison with the effect of bone marrow mononuclear cells (BM-MNC) transplant. Five weeks after induction of MI, rats were allocated to receive intramyocardial injection of 10(6) GFP-expressing cells (BM-MNC or MSC) or medium as control. Heart function (echocardiography and (18)F-FDG-microPET) and histological studies were performed 3 months after transplantation and cell fate was analyzed along the experiment (1 and 2 weeks and 1 and 3 months). The main findings of this study were that both BM-derived populations, BM-MNC and MSC, induced a long-lasting (3 months) improvement in LVEF (BM-MNC: 26.61 +/- 2.01% to 46.61 +/- 3.7%, p < 0.05; MSC: 27.5 +/- 1.28% to 38.8 +/- 3.2%, p < 0.05) but remarkably, only MSC improved tissue metabolism quantified by (18)F-FDG uptake (71.15 +/- 1.27 to 76.31 +/- 1.11, p < 0.01), which was thereby associated with a smaller infarct size and scar collagen content and also with a higher revascularization degree. Altogether, results show that MSC provides a long-term superior benefit than whole BM-MNC transplantation in a rat model of chronic MI.

Mesenchymal Stem Cell Therapy Prevents Interstitial Fibrosis and Tubular Atrophy in a Rat Kidney Allograft Model

“…More recently, it has been suggested that whole BMCs would be more efficient in comparison to MSCs in the reduction of the progression of chronic kidney [9] and heart [25,26] diseases. We, therefore, injected whole BMC as a control group to MSC therapy.…”

Uncultured Marrow Mononuclear Cells Delivered Within Fibrin Glue Hydrogels to Porous Scaffolds Enhance Bone Regeneration Within Critical-Sized Rat Cranial Defects

“…Such an approach greatly diminishes the number and purity of the available multipotent cell population and, in certain cases of cardiovascular repair and regeneration, has been shown to limit the efficacy of cell-based therapies. 38,39 In contrast, Samdani et al directly compared bone marrow mononuclear cells (bmMNCs) with culture-expanded MSCs in a spinal cord injury model and found that bmMNCs offered a greater protective benefit and reduced scar formation relative to MSC-treated injuries. 40 Previous studies in bone and cartilage tissue engineering have shown significant therapeutic benefits associated with the use of uncultured whole bone marrow or bmMNCs.…”

Comparison of Bone Marrow-derived Mononuclear Cells vs. Mesenchymal Stem Cells in Protecting Random-pattern Skin Flap Survival in Rats

“…The pro-angiogenic potentials of BM-MNCs and BMSCs have been demonstrated not only in skin flap survival model but also in the other ischemic diseases [7,8,[13][14][15][16][17]. However, which is the optimal cell source for clinical application is not clear.…”